Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis
Read Article
News
2024
2023
Archive
Search news articles
December 11, 2012
BIOTIE’S TOZADENANT (SYN115) MEETS PRIMARY AND MULTIPLE SECONDARY ENDPOINTS IN PHASE 2B STUDY IN PARKINSON’S DISEASE
December 4, 2012
FLEXION THERAPEUTICS SECURES $20 MILLION IN SERIES B FINANCING
November 13, 2012
PEARL THERAPEUTICS RAISES $65 MILLION SERIES D TO START PT003 PHASE 3
November 4, 2012
TAKEDA TO ACQUIRE ENVOY THERAPEUTICS, INC.
October 11, 2012
C. ROBERT KIDDER JOINS BOARD OF DIRECTORS OF WILDCAT DISCOVERY TECHNOLOGIES, INC.
October 4, 2012
ANAPHORE ANNOUNCES NAME CHANGE TO RUIYI AND NEW ADDITIONS TO SHANGHAI MANAGEMENT TEAM
October 4, 2012
RUIYI (FORMERLY ANAPHORE) AND ARGEN-X ANNOUNCE EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR ARGX-109, A NOVEL ANTI-IL-6 ANTIBODY
September 26, 2012
WILDCAT DISCOVERY TECHNOLOGIES ENTERS JOINT DEVELOPMENT AGREEMENT WITH JAPAN’S ASAHI KASEI CORP. FOR RECHARGEABLE BATTERY TECHNOLOGY
September 18, 2012
IGENICA APPOINTS MARY HAAK-FRENDSCHO, PH.D., AS CHIEF EXECUTIVE OFFICER
September 14, 2012
CYSTIC FIBROSIS FOUNDATION THERAPEUTICS AND PULMATRIX INITIATE COLLABORATION TO ACCELERATE PUR118 IN THE TREATMENT OF CYSTIC FIBROSIS
« Previous Page
1
…
105
106
107
108
109
…
118
Next Page »